Damora Therapeutics, Inc. (DMRA)

NASDAQ: DMRA · Real-Time Price · USD

28.82

-0.63 (-2.12%)

Jul 28, 2026, 12:05 PM EDT - Market open

Damora Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Income	-239.08	-210.87	-22.26	-39.91	-61.21	-52.23
Net Income	-235.09	-209.84	-21.44	-38.35	-61.62	-51.75
Earnings Per Share	5.28	3.98	-18.53	-36.08	-60.75	-51.25
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	532.9	257.62	14.18	33.15	60.22	100.19
Total Debt	0	0.05	0.06	0.07	0.33	0.45
Net Cash (Debt)	532.9	257.57	14.11	33.09	59.9	99.74
Net Cash Growth	4386.06%	1724.93%	-57.34%	-44.76%	-39.95%	-38.82%
Net Cash Per Share	55.47	188.97	12.20	31.13	58.93	98.71

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-24.89	-6.73	-18.62	-36.91	-42.93	-52.31
Capital Expenditures	-	-	-	-	-0.2	-0.22
Free Cash Flow	-24.89	-6.73	-18.62	-36.91	-43.13	-52.53
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	5.78	-	-	-	-